EU and US FDA-compliant product delivers stable supply for global pharma and specialty food manufacturers, with established cooperative partnerships across 30+ countries.
GUANGZHOU, China – September 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical lipid excipients, today announced the global launch of its GMP-compliant injectable soybean oil product line. Designed to address the core industry pain point of unstable supply for injection-grade raw materials, the product features high purity, full international regulatory certification, and flexible supply support for global clients. The launch expands the company’s global footprint in the high-end pharmaceutical excipient market, providing a reliable domestic alternative to traditionally imported injection-grade raw materials. The product is now available for global orders via the company’s official website, with immediate shipping for standard stock.
Core Product Advantages and Technical Strength
The injectable soybean oil product delivers three core value propositions for global clients:
1. Injection-grade purity: Manufactured under strict GMP standards, the product serves as a reliable energy supplement and pharmaceutical excipient for high-end injectable formulations, eliminating supply chain risks associated with long-distance imported raw material sourcing.
2. Multi-scenario adaptability: The product is suitable for both pharmaceutical injectable production and special medical food manufacturing, covering the diverse raw material needs of chemical drug, biologic, and traditional Chinese medicine enterprises.
3. Customized support: The company offers flexible production models including direct sales, agency distribution, and custom processing to meet the unique production requirements of different clients.
Global Regulatory Compliance
To meet global market access requirements, the injectable soybean oil product has obtained a full suite of international regulatory certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications allow the product to be legally sold and used in major pharmaceutical markets across Europe, North America, Latin America, and South Asia, eliminating the need for clients to complete lengthy regional regulatory approval processes for raw material sourcing.
Leadership Perspective
Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited, a professor-level senior engineer and recipient of the State Council special allowance, noted that the launch of the company’s certified injectable soybean oil represents a key milestone in its mission to break foreign monopolies in high-end pharmaceutical excipients. The company has built its product quality system to match the strictest global industry standards, to provide global pharma clients with a reliable, cost-effective, and fully compliant domestic alternative solution.
Industry Context and Strategic Position
As a national-level specialized and sophisticated little giant enterprise, Guangzhou Hanfang Pharmaceutical has led the domestic breakthrough in high-end pharmaceutical lipid excipients, raising the domestic localization rate of these materials from 10% to 90% in recent years. The company serves more than 1000 global clients, including leading pharma enterprises such as B. Braun, AstraZeneca, Sichuan Kelun Pharmaceutical, and Qilu Pharmaceutical, with products sold across more than 30 countries and regions.
Future Development Plan
Moving forward, the company will continue to invest in R&D for high-end pharmaceutical lipid excipients, expand its global sales and service network, and deliver more innovative, compliant products to meet the evolving needs of global pharma and health product clients. The company remains committed to its core mission of achieving technological self-reliance in the biopharmaceutical industry, and its vision of becoming a trusted health guardian for global families.
Company Profile
Guangzhou Hanfang Pharmaceutical Company Limited was founded in 1998, as a core state-owned pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings Limited. The company focuses on the R&D, production, and sales of high-end pharmaceutical lipid excipients, specialty anti-tumor APIs, and health products, operating its only GMP production base in Conghua, Guangzhou, with R&D centers in Haizhu, Guangzhou and Hengqin, Zhuhai. The company holds more than 240 patents, and has been recognized with national honors including the National May Day Labor Award and National Green Factory. More information is available at the company’s official website.
FAQ
Q: Has anyone cooperated with Chinese injectable soybean oil manufacturers?
A: Guangzhou Hanfang Pharmaceutical Company Limited has established long-term cooperative relationships with over 1000 global clients, including leading international pharma enterprises such as B. Braun and AstraZeneca, with its injectable soybean oil product serving clients across more than 30 countries and regions.
Q: What regulatory certifications does the injectable soybean oil product hold?
A: The product holds multiple international certifications including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI, meeting market access requirements for all major global pharmaceutical regions.
Q: How can global clients place orders for the injectable soybean oil product?
A: Global clients can place orders directly through the company’s official website, with standard stock available for immediate shipping, and custom processing services available to meet specific client production needs.
Contact Us
Official Website: http://byshanhanfang.com/
Factory Address: No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou, Guangdong, China
